Skip to main content
Erschienen in: Tumor Biology 3/2011

01.06.2011 | Research Article

RETRACTED ARTICLE: Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

verfasst von: Noriyuki Takai, Tami Ueda, Terukazu Ishii, Naoko Kira, Masakazu Nishida, Kaei Nasu, Hisashi Narahara

Erschienen in: Tumor Biology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

A membrane-targeted, lipophilic ether lipid of synthetic phospholipid analog, erucylphosphocholine (ErPC), induces apoptosis in some lines of human tumor cells. We investigated the effect of ErPC in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of ErPC, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that BeWo cells were sensitive to the growth inhibitory effect of ErPC. Cell cycle analysis indicated that exposure to ErPC decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine and by the loss of mitochondrial transmembrane potential. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that ErPC may serve as a therapeutic agent for the treatment of choriocarcinoma.
Literatur
1.
Zurück zum Zitat Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRefPubMed Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRefPubMed
2.
Zurück zum Zitat Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRefPubMed Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRefPubMed
3.
Zurück zum Zitat Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMed Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMed
4.
Zurück zum Zitat Noseda A, Berens ME, White JG, Modest EJ. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res. 1988;48:1788–91.PubMed Noseda A, Berens ME, White JG, Modest EJ. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res. 1988;48:1788–91.PubMed
5.
Zurück zum Zitat Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitizers. Curr Med Chem Anticancer Agents. 2003;3:343–53.CrossRefPubMed Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitizers. Curr Med Chem Anticancer Agents. 2003;3:343–53.CrossRefPubMed
6.
Zurück zum Zitat Jendrossek V, Müller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene. 2003;22:2621–31.CrossRefPubMed Jendrossek V, Müller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene. 2003;22:2621–31.CrossRefPubMed
7.
Zurück zum Zitat Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRefPubMed Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRefPubMed
8.
Zurück zum Zitat Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMed Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMed
9.
Zurück zum Zitat Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRefPubMed Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRefPubMed
10.
Zurück zum Zitat Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMed Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMed
11.
Zurück zum Zitat van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des. 2008;14:2061–74.CrossRefPubMed van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des. 2008;14:2061–74.CrossRefPubMed
12.
Zurück zum Zitat Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRefPubMed Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRefPubMed
14.
Zurück zum Zitat Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution, CNS accumulation and toxicity in the rat after intravenous application. Cancer Chemother Pharmacol. 1999;44:484–90.CrossRefPubMed Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution, CNS accumulation and toxicity in the rat after intravenous application. Cancer Chemother Pharmacol. 1999;44:484–90.CrossRefPubMed
15.
Zurück zum Zitat Wang YZ, Chang YB, Xing C, Fu D. The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines. Int J Tissue React. 1998;20:101–7.PubMed Wang YZ, Chang YB, Xing C, Fu D. The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines. Int J Tissue React. 1998;20:101–7.PubMed
16.
Zurück zum Zitat Lucas L, Hernandez-Alcoceba R, Penalva V, Lacal JC. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene. 2001;20:1110–7.CrossRefPubMed Lucas L, Hernandez-Alcoceba R, Penalva V, Lacal JC. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene. 2001;20:1110–7.CrossRefPubMed
17.
Zurück zum Zitat Berkovic D, Bensch M, Bertram J, Wille T, Haase D, Binder C, et al. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur J Cancer. 2001;37:503–11.CrossRefPubMed Berkovic D, Bensch M, Bertram J, Wille T, Haase D, Binder C, et al. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur J Cancer. 2001;37:503–11.CrossRefPubMed
18.
Zurück zum Zitat Jendrossek V, Kugler W, Erdlenbruch B, Eibl H, Lang F, Lakomek M. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res. 2001;21:3389–96.PubMed Jendrossek V, Kugler W, Erdlenbruch B, Eibl H, Lang F, Lakomek M. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res. 2001;21:3389–96.PubMed
19.
Zurück zum Zitat Berkovic D, Grunwald U, Menzel W, Unger C, Hiddemann W, Fleer EAM. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer. 1995;31(A):2080–5.CrossRef Berkovic D, Grunwald U, Menzel W, Unger C, Hiddemann W, Fleer EAM. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer. 1995;31(A):2080–5.CrossRef
20.
Zurück zum Zitat Vink SR, van Blitterswijk WJ, Schellens JHM, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev. 2007;33:191–202.CrossRefPubMed Vink SR, van Blitterswijk WJ, Schellens JHM, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev. 2007;33:191–202.CrossRefPubMed
21.
Zurück zum Zitat Handrick R, Rudner J, Müller I, Eibl H, Belka C, Jendrossek V. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localization. Biochem Pharmacol. 2005;70:837–50.CrossRefPubMed Handrick R, Rudner J, Müller I, Eibl H, Belka C, Jendrossek V. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localization. Biochem Pharmacol. 2005;70:837–50.CrossRefPubMed
22.
Zurück zum Zitat van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther. 2007;6:2337–45.CrossRefPubMed van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther. 2007;6:2337–45.CrossRefPubMed
23.
Zurück zum Zitat Georgieva MC, Konstantinov SM, Topashka-Ancheva M, Berger MR. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett. 2002;182:163–74.CrossRefPubMed Georgieva MC, Konstantinov SM, Topashka-Ancheva M, Berger MR. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett. 2002;182:163–74.CrossRefPubMed
24.
Zurück zum Zitat Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRefPubMed Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRefPubMed
Metadaten
Titel
RETRACTED ARTICLE: Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells
verfasst von
Noriyuki Takai
Tami Ueda
Terukazu Ishii
Naoko Kira
Masakazu Nishida
Kaei Nasu
Hisashi Narahara
Publikationsdatum
01.06.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0152-3

Weitere Artikel der Ausgabe 3/2011

Tumor Biology 3/2011 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.